These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21285137)

  • 1. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
    Anderson H; Hills M; Zabaglo L; A'hern R; Leary AF; Haynes BP; Smith IE; Dowsett M
    Ann Oncol; 2011 Aug; 22(8):1770-6. PubMed ID: 21285137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
    Endo Y; Toyama T; Takahashi S; Sugiura H; Yoshimoto N; Iwasa M; Kobayashi S; Fujii Y; Yamashita H
    Int J Clin Oncol; 2011 Oct; 16(5):512-8. PubMed ID: 21431343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
    Arnedos M; Drury S; Afentakis M; A'Hern R; Hills M; Salter J; Smith IE; Reis-Filho JS; Dowsett M
    Ann Oncol; 2014 Mar; 25(3):605-610. PubMed ID: 24525703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
    Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
    Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
    J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
    Lopez-Knowles E; Detre S; Hills M; Schuster EF; Cheang MCU; Tovey H; Kilburn LS; Bliss JM; Robertson J; Mallon E; Skene A; Evans A; Smith I; Dowsett M
    Breast Cancer Res; 2022 Sep; 24(1):61. PubMed ID: 36096872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
    Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
    PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
    Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.
    Kurozumi S; Yamaguchi Y; Matsumoto H; Kurosumi M; Hayashi SI; Fujii T; Horiguchi J; Shirabe K; Inoue K
    PLoS One; 2019; 14(5):e0217279. PubMed ID: 31112577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
    Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
    World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.
    Burcombe RJ; Makris A; Richman PI; Daley FM; Noble S; Pittam M; Wright D; Allen SA; Dove J; Wilson GD
    Br J Cancer; 2005 Jan; 92(1):147-55. PubMed ID: 15611798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer patients.
    Boland MR; Ryan ÉJ; Nugent T; Gilroy D; Kelly ME; Kennedy J; Maguire A; Alazawi D; Boyle TJ; Connolly EM
    J Surg Oncol; 2020 Oct; 122(5):861-868. PubMed ID: 32613608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
    Bergamino MA; López-Knowles E; Morani G; Tovey H; Kilburn L; Schuster EF; Alataki A; Hills M; Xiao H; Holcombe C; Skene A; Robertson JF; Smith IE; Bliss JM; Dowsett M; Cheang MCU;
    EBioMedicine; 2022 Sep; 83():104205. PubMed ID: 35985932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.